iBio

Update in progress

IBIO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

iBio, Inc. is a preclinical biotechnology company developing AI-driven antibody solutions for cardiometabolic disease and obesity. Its platforms include EngageTx (CD3 T-cell engager panel), ShieldTx (conditioned-activated antibodies), StableHu (AI antibody optimization), and AI epitope steering. Pipelines include IBIO-101, CCR8, and MUC16 antibodies; EGFRvIII and TROP-2 x CD3 bispecifics. Collaboration with AstralBio. Based in San Diego, formed 2008, renamed 2009.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.39; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive